RDP-02004

RDP-02004 is an orally bioavailable, non-covalent small molecule degrader of the c-Myc protein, developed by RDP Pharma AG using their Prompt Degrader™ platform. Unlike conventional PROTACs or molecular glues, RDP-02004 works by stabilizing transient, non-native conformations of the intrinsically disordered protein (IDP) c-Myc, specifically promoting the formation of degradation-prone multimers. This stabilization triggers clearance through multiple protein quality-control pathways, including the ubiquitin-proteasome system and aggrephagy-like mechanisms. In preclinical studies, RDP-02004 demonstrated potent anti-tumor activity across various MYC-dependent cancers, such as multiple myeloma, lung cancer, and triple-negative breast cancer, while maintaining a favorable selectivity profile over non-transformed cells.